Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Poland
  4. Warsaw Stock Exchange
  5. Mabion S.A.
  6. Summary
    MAB   PLMBION00016

MABION S.A.

(MAB)
  Report
Delayed Warsaw Stock Exchange  -  05/17 11:55:43 am EDT
27.98 PLN   +1.75%
04/21Mabion S.A. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
2021Mabion S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
CI
2021MABION S.A.(WSE : MAB) added to S&P Global BMI Index
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Warsaw Stock Exchange
05/11/2022 05/12/2022 05/13/2022 05/16/2022 05/17/2022 Date
28(c) 27(c) 28.28(c) 27.5(c) 27.98(c) Last
47 644 45 287 43 887 29 724 19 428 Volume
-1.75% -3.57% +4.74% -2.76% +1.75% Change
More quotes
Estimated financial data (e)
Sales 2021 8,00 M 1,81 M 1,81 M
Net income 2021 -59,0 M -13,4 M -13,4 M
Net Debt 2021 20,8 M 4,71 M 4,71 M
P/E ratio 2021 -7,62x
Yield 2021 -
Sales 2022 286 M 64,8 M 64,8 M
Net income 2022 59,0 M 13,4 M 13,4 M
Net Debt 2022 18,4 M 4,17 M 4,17 M
P/E ratio 2022 7,69x
Yield 2022 -
Capitalization 452 M 102 M 102 M
EV / Sales 2021 59,1x
EV / Sales 2022 1,65x
Nbr of Employees 213
Free-Float 63,7%
More Financials
Company
Mabion SA is a Poland-based company engaged in the research and development of biotechnological and biopharmaceutical medicinal products. Mabion SA was founded by four pharmaceutical companies, including Celon Pharma Ltd, Polfarmex Co, Genexo Ltd and IBSS Biomed Co, as well as two companies focused on research and development in biotechnology field, including BioCentrum Ltd and Biotech Consulting Ltd. The Company... 
Read more
More about the company
All news about MABION S.A.
04/21Mabion S.A. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
2021Mabion S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended Septem..
CI
2021MABION S.A.(WSE : MAB) added to S&P Global BMI Index
CI
2021Mabion S.A. Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
2021Big pharma and private equity seek healthy returns in Europe's east
RE
2021MABION Announces Executive Changes
CI
2021Mabion S.A. Reports Earnings Results for the Full Year Ended December 31, 2020
CI
2021Mabion S.A. Auditor Raises 'Going Concern' Doubt
CI
2021Polish Biotech Mabion Enters Deal To Manufacture Novavax COVID-19 Jab
MT
2021Mabion Biotech Signs Deal with Novavax on Covid-19 Vaccine Technology Transfer
CI
2020Mabion S.A. Reports Earnings Results for the Third Quarter Ended September 30, 2020
CI
2020Mabion S.A. Reports Earnings Results for the Second Quarter Ended June 30, 2020
CI
2020MABION S A : otrzyma do 15 mln zł pożyczek od akcjonariuszy na dalszy rozwój Spó..
PU
2020MABION S A : Zawarcie umów pożyczek od głównych akcjonariuszy Spółki
PU
2020Mabion S.A. announced that it expects to receive PLN 1.563755 million in funding
CI
More news
News in other languages on MABION S.A.
04/21Mabion S.A. annonce ses résultats pour l'année complète se terminant le 31 décembre 202..
2021Les grandes entreprises pharmaceutiques et les fonds d'investissement recherchent des r..
2021AKTIEN OSTEUROPA SCHLUSS : Mehrheitlich Gewinne
2021AKTIEN OSTEUROPA SCHLUSS : Ohne klare gemeinsame Richtung
More news
Analysis
Big pharma and private equity seek healthy returns in Europe's east
Chart MABION S.A.
Duration : Period :
Mabion S.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MABION S.A.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Last Close Price 27,98 PLN
Average target price 68,50 PLN
Spread / Average Target 145%
EPS Revisions
Managers and Directors
Krzysztof Kaczmarczyk President-Management Board & CEO
Grzegorz Mariusz Grabowicz Finance Director
Robert Leszek Konski Independent Member-Supervisory Board
Slawomir Jaros Chief Operating & Scientific Officer
David John James Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
MABION S.A.-54.99%99
GILEAD SCIENCES, INC.-12.99%78 068
REGENERON PHARMACEUTICALS, INC.5.71%70 575
VERTEX PHARMACEUTICALS19.24%65 005
WUXI APPTEC CO., LTD.-16.20%42 275
BIONTECH SE-41.35%36 745